A Comparative Study of Biologic Regulation in US, Canada, Australia, Europe and Singapore
Abstract
Extensive research in chemistry, manufacturing, controls, preclinical science, and clinical trials is required when developing a novel biological medication. Drug reviewers in regulatory bodies throughout the world and all regulatory bodies are entrusted with determining whether research evidence establishes new drug product safety, effectiveness, and quality control in order to protect public health. Among the world every province has its own regulatory organization in charge of enforcing laws and regulations and developing guidelines for drug marketing. There are some particular requirements sets by regulatory authority that must be satisfied when submitting in the particular nation. The world is split into various approval procedures, it is pivotal for manufacturers to carefully assess market interest, expenditures, target zones, and regulatory standards before establishing biologics. Despite the existence and widespread adoption of an ICH-CTD standard format, some limitations are included. This article discusses the comparison considerations used for biological product approval in the United States, Canada, Europe, Australia, and Singapore.
Downloads
References
2. Patel P. K. King C. R. Feldman S. R. Biologics and biosimilars. Journal of Dermatological Treatment. 2015; 26 (4):299–302.
3. Salman Basha S. Shakeel S. M. Nagabhushanam M. V. Nagarjuna Reddy D. Bonthagarala B. The Assessment of Current Regulatory Guidelines for Biosimilars-A Global Scenario. World Journal of Pharmaceutical Research. 2017; 6(1):351–369.
4. Wang J. Chow S. C. On the regulatory approval pathway of biosimilar products. Pharmaceuticals. 2012; 5:353–368.
5. Vishal P. Rahulgiri G. Pratik M. Kumar B. J. A Review on Drug Approval Process for US, Europe and India. International Journal of Drug Regulatory Affairs. 2014; (1):1-11.
6. Kusuma M. S. Sravani M. Regulatory Requirements for Registration of Biologics in US. International Journal of Pharma and Chemical Research. 2017;3(3):523-540.
7. Gupta N. V., Konangi S. Raviteja M. N. Comparison of Global Regulatory Approvals for Biosimilar Products. International Journal of PharmTech Research. 2013; 5(3):924-935.
8. Guidances (Drugs) [Internet]. USFDA; 2020 [cited 2022 March 07]. Available from:
https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm
9. Biologicals: finished product [Internet]. European Medicines Agency; 2019 Jan 01 [cited 2022 March 7]. Available from:
https://www.ema.europa.eu/en/human-regulatory/research-development/scientific-guidelines/biologicals/biologicals-finished-product
10. Maurya S. K. Shukla V. K. Maurya S. K. Kaushik P. Regulatory aspects for Biologic Product licensing in Australia. International Journal of Drug Regulatory Affairs. 2019;7(2):1-6.
11. Patel P. Badjatya J. K. Hinge M. Comparative study of Regulatory requirements of Drug Product in Emerging Market. International Journal of Drug Regulatory Affairs. 2019;7(3):48-62.
12. Guidance documents for therapeutic products [Internet]. Health Sciences Authority Singapore; 2021 [cited 2022 March 07]. Available from:
https://www.hsa.gov.sg/therapeutic-products/guidance-documents
13. Tripathi C. Girme A. Champaneri S. Patel R. J. Hingorani L. Nutraceutical regulations: An opportunity in ASEAN countries. Nutrition. 2020;74:110729.
14. Agrawal M. Alexander A. Khan J. Giri T. K. Siddique S. Dubey S. K. Patel R. J. Gupta U. Saraf S. Saraf S. Recent biomedical applications on stem cell therapy: a brief overview. Current Stem Cell Research & Therapy. 2019; 14(2):127-136.
15. Patel R. Patel A. Gohil T. Regulatory requirement for the approval of generic drug in Cambodia as per ASEAN common technical dossier (ACTD). International Journal of Drug Regulatory Affairs. 2018;6(2):67-71
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The International Journal of Drug Regulatory affairs require a formal written transfer of copyright from the author(s) for each article published. We therefore ask you to complete and return this form, retaining a copy for your records. Your cooperation is essential and appreciated. Any delay will result in a delay in publication.
I/we have read and agree with the terms and conditions stated Page 2 of this agreement and I/we hereby confirm the transfer of all copyrights in and relating to the above-named manuscript, in all forms and media, now or hereafter known, to the International Journal of Drug Regulatory affairs, effective from the date stated below. I/we acknowledge that the IJDRA is relying on this agreement in publishing the above-named manuscript. However, this agreement will be null and void if the manuscript is not published in the IJDRA.
Download link for COPYRIGHT FORM
